雷帕鸣在治疗肾移植这方面效果如何？

Rapamin (sirolimus tablets, sirolimus) is suitable for patients undergoing kidney transplantation. It is recommended to be used in combination with cyclosporine and corticosteroids to prevent organ rejection. The dosage and dosage of rapamycin are recommended to be used in combination with cyclosporine and corticosteroids. Take orally, once daily. It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose that should be taken for the first time is three times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day.

In cells, sirolimus binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian sirolimus BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from the G1 phase to the S phase in the cell cycle.

How effective is Rapamin in the treatment of kidney transplantation?

The clinical trial was conducted in 34 research units in Australia, Canada, Europe and the United States, and 576 patients were included. Randomly assigned before transplantation: 227 patients received rapamin (sirolimus tablets, sirolimus) 2 mg/day, 219 patients received rapamin (sirolimus tablets, sirolimus) 5 mg/day, and 130 patients received placebo. In both trials, antilymphocyte antibody induction therapy was contraindicated. In both trials, the primary efficacy endpoint was the rate of treatment failure within the first 6 months after transplantation. Treatment failure was defined as the first episode of acute rejection (confirmed by biopsy), graft loss, or death. Trial analysis results: Compared with azathioprine and placebo, rapamycin (sirolimus tablets, sirolimus) dose levels of 2 mg/day and 5 mg/day significantly reduced the incidence of treatment failure in the 6 months after transplantation.